Safety, Tolerability and Pharmacokinetics of Single Rising Oral Doses of BI 691751 in Healthy Asian Male Volunteers in a Randomised, Double-blind, Placebo-controlled Design.
Phase of Trial: Phase I
Latest Information Update: 17 Dec 2015
At a glance
- Drugs BI 691751 (Primary)
- Indications Atherosclerosis; Cardiovascular disorders
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 19 May 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 19 Mar 2014 Status changed from not yet recruiting to recruiting, as per ClinicalTrials.gov record.
- 14 Feb 2014 New trial record